Investigating CDK inhibitors also requires understanding the role of these inhibitors in non-HPV-related HNSCC, where the regulation of cyclin D1/CDK4/6 plays a significant role. This evidence concerns the gene CCND1 and head and neck squamous cell carcinoma.